Giuseppe Curigliano
朱塞佩·库里格利亚诺
MD, PhD
Professor of Medical Oncology; Head, Early Drug Development Division肿瘤内科学教授；早期药物研发部主任
👥Biography 个人简介
Internationally recognized breast oncologist at IEO Milan, leading early drug development and clinical trials in HER2+ breast cancer, immunotherapy combinations, and novel TKI strategies. Key contributor to ESMO breast cancer guidelines.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
HER2+ Breast Cancer & Immunotherapy
Conducted pivotal early-phase trials combining HER2-targeted TKIs with immunotherapy; contributed to ESMO guidelines shaping European breast cancer treatment standards and led multiple Phase I/II ADC studies.
Representative Works 代表性著作
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer (HER2CLIMB)
New England Journal of Medicine (2020)
Co-investigator on HER2CLIMB establishing tucatinib combination as standard in HER2+ MBC including brain metastases.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 朱塞佩·库里格利亚诺 的研究动态
Follow Giuseppe Curigliano's research updates
留下邮箱，当我们发布与 Giuseppe Curigliano（European Institute of Oncology (IEO), University of Milan）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment